What does biotech think about ‘right-to-try'? It might surprise you
“Right-to-try” has made its way back to the headlines, filling our Twitter feeds with opinions on whether the House should reject or embrace a bill that would allow patients access to unapproved therapies. We know what politicians think, and what the public thinks. What does biotech think?
We asked ourselves that question here at Endpoints News, so we crafted a brief survey posing this question to our readers: Do you approve or disapprove of “right-to-try”?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
